Relmada Therapeutics
RLMD
Relmada Therapeutics (RLMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.11
- EPS estimate
- −$0.20
- EPS surprise
- +44.86%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.20 | −$0.11 | +44.86% | $0.00 | SEC |
| Q1 2026 | May 12, 2026 | −$0.20 | −$0.22 | −9.84% | $0.00 | SEC |
| Q4 2025 | Mar 19, 2026 | −$0.15 | −$0.27 | −81.70% | $0.00 | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.42 | −$0.30 | +29.28% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.46 | −$0.30 | +34.78% | $0.00 | SEC |
| Q1 2025 | May 12, 2025 | −$0.48 | −$0.58 | −20.83% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.67 | −$0.62 | +7.92% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.68 | −$0.72 | −6.67% | $0.00 | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.83 | −$0.59 | +28.70% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.85 | −$0.72 | +15.29% | $0.00 | SEC |
| Q4 2023 | Mar 19, 2024 | −$0.83 | −$0.84 | −1.20% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.91 | −$0.73 | +20.13% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.90 | −$0.84 | +6.15% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.89 | −$0.87 | +2.25% | $0.00 | SEC |
| Q4 2022 | Mar 23, 2023 | −$1.33 | −$1.28 | +3.64% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.45 | −$1.31 | +9.66% | $0.00 | — |
| Q2 2022 | Aug 11, 2022 | −$1.27 | −$1.33 | −4.49% | $0.00 | — |
| Q1 2022 | May 5, 2022 | −$1.27 | −$1.40 | −10.61% | $0.00 | — |
| Q4 2021 | Mar 23, 2022 | −$1.83 | −$1.80 | +1.64% | $0.00 | — |
| Q3 2021 | Nov 12, 2021 | −$1.60 | −$2.44 | −52.82% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Relmada Therapeutics (RLMD) last report earnings?
Relmada Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did RLMD beat earnings estimates?
Yes. Relmada Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.20 estimate — a 44.86% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.